Regeneron Pharmaceuticals (REGN) has drawn fresh attention after regulators in the US and Europe accepted cemdisiran for review in generalized myasthenia gravis, supported by Phase 3 results published in The Lancet.

Regeneron Pharmaceuticals' share price is US$649.81, with a 7 day share price return of 2.85% and a 30 day share price return of 2.26%. However, momentum has faded given the 90 day share price return is down 14.53% and the year to date share price return is down 16.30%. The 1 year total shareholder return of 21.42% contrasts with a 3 year total shareholder return that is down 6.85% and a 5 year total shareholder return of 14.14%.

If you are comparing Regeneron with other healthcare names benefiting from similar themes, this is a good moment to see what stands out in 40 healthcare AI stocks

Regeneron Pharmaceuticals has a large, profitable drug portfolio and new catalysts like cemdisiran drawing fresh attention, yet the stock has slipped from recent highs. Does that set up an appealing entry point or signal a value trap?

Most Popular Narrative: 22% Undervalued

The most followed narrative values Regeneron Pharmaceuticals at $833.31 per share, well above the last close of $649.81, and anchors that gap in detailed earnings and growth assumptions.

Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine. This, in turn, supports future revenue growth and pipeline-driven earnings potential.

Want to see what underpins that valuation gap? The narrative leans on steady top line expansion, firmer margins, and a future earnings multiple that investors may not be expecting.

Result: Fair Value of $833.31 (UNDERVALUED)

However, Regeneron Pharmaceuticals still faces meaningful risks, including pressure on the EYLEA franchise and uncertainty around high cost R&D translating into commercially successful late stage drugs.

Next Steps

If the mix of optimism and caution around Regeneron Pharmaceuticals feels familiar, do not wait to check the data for yourself. Stress test the narrative, then weigh those potential upsides against the risks by reviewing the 4 key rewards

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

If you find the risk reward profile of Regeneron Pharmaceuticals appealing, you can use the Simply Wall St Screener to explore other targeted opportunities across the market.

• Spot potential mispricings early by scanning a focused list of 41 high quality undervalued stocks before others notice them.
• Strengthen your defensive core by reviewing companies in the 74 resilient stocks with low risk scores that score well on measures of resilience.
• Stay ahead of the crowd by checking the screener containing 18 high quality undiscovered gems and seeing which stocks stand out on fundamentals before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.